Tuesday, November 10, 2026, 1:00 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Samuel Caughron, MD, FCAP, Chief Strategy Officer, MAWD Pathology, Medical Director of Laboratory, AdventHealth Kansas City, Medical Director of Laboratory, Labcorp, President, Member & Director, Pathology Ventures, LLC
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, November 18, 2026, 12:00 PM-1 PM ET
Join leading pathology experts, Savitri Krishnamurthy, MD, and Marilyn Bui, MD, PhD, for a webinar exploring potential challenges in HER2 IHC testing for breast cancer, emerging evidence supporting digital and computational pathology as assistive tools for pathologists in HER2 IHC assessment, and practical considerations for real-world implementation and adoption.
Webinar presenters Savitri Krishnamurthy, MD, Professor of Pathology, Department of Anatomical Pathology The University of Texas MD Anderson Cancer Center, Houston, Texas, and Marilyn Bui, MD, PhD, Surgical Pathologist and Cytopathologist Member and Professor, Departments of Pathology, Machine Learning, and Translational Pathology, Scientific Director, Analytic Microscopy Core Chair, Women in Oncology Executive Board Moffitt Cancer Center, Tampa, Florida
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speakers are being compensated for their presentations. The program is not CME accredited and may not be used for CME credit.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
May 2015—Seegene announced that the Food and Drug Administration has granted 510(k) market clearance for its TOCE-based herpes simplex virus types 1 and 2 assay. This is the first product Seegene has taken through the FDA, and it opens the way for the company’s other planned FDA submissions of multiplex real-time PCR reagents.
May 2015—Myriad RBM launched immunoassay services based on Quanterix’s ultrasensitive Simoa (single molecule array) platform, which enables the accurate measurement of protein biomarkers that were previously difficult or even impossible to detect in blood samples.
May 2015—The diagnostics division of Siemens Healthcare announced the availability of two urine testing solutions for U.S. central laboratories—the Clinitek Novus Automated Urine Chemistry Analyzer and the Clinitek AUWi Pro Automated Urine Workstation.
May 2015—The Clinical and Laboratory Standards Institute has published a new document, “Process Management (QMS18-Ed1).” This guideline describes four requirements for managing laboratory processes and provides suggestions for effectively meeting regulatory and accreditation requirements, optimizing efficient use of resources, and contributing to patient safety and positive outcomes.
May 2015—Enzo Biochem announced the development of the FlowScript assay in detection of messenger RNA from HPV oncogenes E6 and E7. The FlowScript technology platform is a proprietary flow-cytometry-based molecular detection system for the multiplex analysis of cell function and identity; the HPV E6/E7 assay is the first product to use this novel platform. Analysis is performed on a small volume of a liquid cytology specimen and can be incorporated as a reflex test measure following abnormal Pap smear results.
May 2015—Seegene announced that Health Canada has approved its six-target Allplex Respiratory Panel 5 assay, which identifies influenza virus A and B, RSV A and B, and influenza A virus subtypes H1 and H3.
May 2015—WaveSense, a manufacturer of in vitro diagnostic cell targeting, enrichment, and isolation products for pathology, urology, and oncology, added a product to its line of cell enrichment applications delivered through its patented EpiSep medical product line.
May 2015—EKF Diagnostics has introduced the Stanbio Chemistry Glycated Serum Protein LiquiColor test, a diabetic biomarker test that provides a two- to three-week indicator of average blood glucose, closing the information gap between daily blood glucose testing and the two- to three-month HbA1c reading. GSP serves as an accurate intermediate marker of glycemia in instances where HbA1c may be of limited value, such as pregnancy, reduced RBC lifespan, and hemodialysis.
May 2015—The Methotrexate ELISA kit from Enzo Life Sciences enables the monitoring of methotrexate levels during treatment of cancer and rheumatoid arthritis. The assay is also appropriate for the detection of methotrexate contamination after its use as a selective agent for recombinant protein production in mammalian cell lines.
May 2015—Sarstedt is offering two urine collection systems—the Urine Monovette and the V-Monovette. The Urine Monovette enables hygienic urine collection and testing without needles, adapters, or cups or transfers. All tubes are manufactured from impact-resistance, medical-grade plastics and feature secure screw caps for safe handling. After collection using a syringe technique, the plunger handle is removed to create a primary tube for transport, direct analysis, and centrifugation. A Luer-lock version is also available for needleless collection from Foley catheters.
